EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery and antitumor evaluation of a mitochondria-targeting ruthenium complex for effective cancer therapy

Peng Liu, Shangbo Zhou, Zhijun Zhou, Zihan Jin, Wei Chen, Zihang Li, Jiaqi Xu, Feng Chen, You Li, Yingfei Wen, Shiqiang Zhang, Changhua Zhang und 3 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Peng Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China. Hauptthemen laut MEDLINE: Mitochondria, Antineoplastic Agents, Ruthenium, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Planning Project of Shenzhen Municipality, Shenzhen Science and Technology Innovation Committee, Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ruthenium-based metallodrugs have garnered attention as a promising alternative for anticancer therapy, aiming to overcome chemoresistance and severe side effects linked to platinum-based drugs. However, ruthenium complexes tested in clinical trials to date have yielded unsatisfactory results. This study synthesized a positively charged ruthenium complex (Ru-2) that effectively penetrated cancer cells and exhibited superior cytotoxicity to cisplatin in vitro against cancer cell lines and organoids. Ru-2 selectively targeted mitochondria, disrupting their function by depolarizing mitochondrial membrane potential, elevating reactive oxygen species production, and impairing both oxidative phosphorylation and the tricarboxylic acid cycle. Furthermore, Ru-2 triggered endoplasmic reticulum (ER) stress and apoptosis. Integrative transcriptomic and proteomic analyses, performed using RNA sequencing and mass spectrometry, identified key molecular changes in cancer cells treated with Ru-2. For enhanced in vivo application, we developed a transferrin-based nanomedicine formulation, TF/Ru-2, incorporating Ru-2 into transferrin. In vivo studies demonstrated that both Ru-2 and TF/Ru-2 exhibited superior antitumor efficacy and improved biosafety compared to cisplatin. This study presents a novel ruthenium complex and a transferrin-based drug delivery platform with significant potential for future cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaAntineoplastic AgentsRutheniumNeoplasmsCoordination ComplexesHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysApoptosisCisplatinMembrane Potential, MitochondrialReactive Oxygen SpeciesEndoplasmic Reticulum StressMice, Nude

Stichwörter der Autor:innen

ChemotherapyGastric cancerMitochondriaRuthenium complexTransferrin

Substanzen

Antineoplastic AgentsRutheniumCisplatinReactive Oxygen SpeciesCoordination Complexes

Autor:innen und Institutionen

  • Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China.
  • Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
  • Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China.
  • Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China; Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107…
  • Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China. Electronic address: libb26@mail.sysu.edu.cn.
  • Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China. Electronic address: zhaoj265@mail.sysu.edu.cn.

Förderung

  • Science and Technology Planning Project of Shenzhen Municipality
  • Shenzhen Science and Technology Innovation Committee
  • Sun Yat-sen University
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Liu, P., Zhou, S., Zhou, Z., Jin, Z., Chen, W., Li, Z., Xu, J., Chen, F., Li, Y., Wen, Y., Zhang, S., Zhang, C., Li, B., Zhao, J., & Chen, H. (2025). Discovery and antitumor evaluation of a mitochondria-targeting ruthenium complex for effective cancer therapy. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217582

Vancouver

Liu P, Zhou S, Zhou Z, Jin Z, Chen W, Li Z, et al. Discovery and antitumor evaluation of a mitochondria-targeting ruthenium complex for effective cancer therapy. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217582

BibTeX
@article{Liu2025,
  author = {Liu, Peng and Zhou, Shangbo and Zhou, Zhijun and Jin, Zihan and Chen, Wei and Li, Zihang and Xu, Jiaqi and Chen, Feng and Li, You and Wen, Yingfei and Zhang, Shiqiang and Zhang, Changhua and Li, Binbin and Zhao, Jing and Chen, Hengxing},
  title = {Discovery and antitumor evaluation of a mitochondria-targeting ruthenium complex for effective cancer therapy},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217582}
}
Kostenlos starten →